Quantitative imaging of pO₂ in orthotopic murine gliomas: hypoxia correlates with resistance to radiation

References

• Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro-Oncology 2013;15:ii1–i56.
   PubMed Web of Science ®Google Scholar
• Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci 2010;17:417–421.
   PubMed Web of Science ®Google Scholar
• Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, et al. Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1alpha-ZEB1 axis. Cancer Lett 2015;359:107–116.
   PubMed Web of Science ®Google Scholar
• Yang L, Lin C, Wang L, Guo H, Wang X. Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res 2012;318:2417–2426.
   PubMed Web of Science ®Google Scholar
• Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011;11:393–410.
   PubMed Web of Science ®Google Scholar
• Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H, et al. 18F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging 2012;39:760–770.
   PubMed Web of Science ®Google Scholar
• Spence AM, Muzi M, Swanson KR, O'Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoro-misonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 2008;14:2623–2630.
   PubMed Web of Science ®Google Scholar
• Stokes AM, Hart CP, Quarles CC. Hypoxia imaging with PET correlates with antitumor activity of the hypoxia-activated prodrug Evofosfamide (TH-302) in rodent glioma models. Tomography 2016;2:229–237.
   PubMed Web of Science ®Google Scholar
• Valable S, Petit E, Roussel S, Marteau L, Toutain J, Divoux D, et al. Complementary information from magnetic resonance imaging and (18) F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model. Nucl Med Biol 2011;38:781–793.
   PubMed Web of Science ®Google Scholar
• Tóth V, Förschler A, Hirsch NM, den Hollander J, Kooijman H, Gempt J, et al. MR-based hypoxia measures in human glioma. J NeuroOncol 2013;115:197–207.
   PubMed Web of Science ®Google Scholar
• Preibisch C, Shi K, Kluge A, Lukas M, Wiestler B, Göttler J, et al. Characterizing hypoxia in human glioma: a simultaneous multimodal MRI and PET study. NMR Biomed 2017 [Aug 14]. [Epub ahead of print]. doi: 10.1002/nbm.3775
   PubMedGoogle Scholar
• Krishna MC, Subramanian S, Kuppusamy P, Mitchell JB. Magnetic resonance imaging for in vivo assessment of tissue oxygen concentration. Semin Radiat Oncol 2001;11:58–69.
   PubMed Web of Science ®Google Scholar
• Krishna MC, Matsumoto S, Yasui H, Saito K, Devasahayam N, Subramanian S, Mitchell JB. Electron paramagnetic resonance imaging of tumor pO2. Radiat Res 2012;177:376–386.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Hyodo F, Subramanian S, Devasahayam N, Munasinghe J, Hyodo E, et al. Low-field paramagnetic resonance imaging of tumor oxygenation and glycolytic activity in mice. J Clin Invest 2008;118:1965–1973.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Saito K, Takakusagi Y, Matsuo M, Munasinghe JP, Morris HD, et al. In vivo imaging of tumor physiological, metabolic, and redox changes in response to the anti-angiogenic agent sunitinib: longitudinal assessment to identify transient vascular renormalization. Antioxid Redox Signal 2014;21:1145–1155.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Saito K, Yasui H, Morris HD, Munasinghe JP, Lizak M, et al. EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate. Magn Reson Med 2013;69:1443–1450.
   PubMed Web of Science ®Google Scholar
• Dimberg A. The glioblastoma vasculature as a target for cancer therapy. Biochem Soc Trans 2014;42:1647–1652.
   PubMed Web of Science ®Google Scholar
• Devasahayam N, Subramanian S, Murugesan R, Cook JA, Afeworki M, Tschudin RG, et al. Parallel coil resonators for time-domain radiofrequency electron paramagnetic resonance imaging of biological objects. J Magn Reson 2000;142:168–176.
   PubMed Web of Science ®Google Scholar
• Devasahayam N, Subramanian S, Murugesan R, Hyodo F, Matsumoto K, Mitchell JB, Krishna MC. Strategies for improved temporal and spectral resolution in in vivo oximetric imaging using time-domain EPR. Magn Reson Med 2007;57:776–783.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Subramanian S, Devasahayam N, Aravalluvan T, Murugesan R, Cook JA, et al. Electron paramagnetic resonance imaging of tumor hypoxia: enhanced spatial and temporal resolution for in vivo pO2 determination. Magn Reson Med 2006;55:1157–1163.
   PubMed Web of Science ®Google Scholar
• Subramanian S, Devasahayam N, Murugesan R, Yamada K, Cook J, Taube A, et al. Single-point (constant-time) imaging in radiofrequency Fourier transform electron paramagnetic resonance. Magn Reson Med 2002;48:370–379.
   PubMed Web of Science ®Google Scholar
• Begg AC, Stewart FA, Vens C. Strategies to improve radiotherapy with targeted drugs. Nat Rev Cancer 2011;11:239–253.
   PubMed Web of Science ®Google Scholar
• Fokas E, McKenna WG, Muschel RJ. The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. Cancer Metastasis Rev 2012;31:823–842.
   PubMed Web of Science ®Google Scholar
• Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J. Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 2011;101:369–375.
   PubMed Web of Science ®Google Scholar
• Welz S, Mönnich D, Pfannenberg C, Nikolaou K, Reimold M, La Fougère C, et al. Prognostic value of dynamic hypoxia PET in head and neck cancer: results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial. Radiother Oncol J Eur Soc Ther Rad Oncol 2017;124:526–532.
   PubMed Web of Science ®Google Scholar
• Mahling M, Fuchs K, Thaiss WM, Maier FC, Feger M, Bukala D, et al. A comparative pO2 probe and [18F]-fluoro-Azomycinarabino-furanoside ([18F]FAZA) PET study reveals anesthesia-induced impairment of oxygenation and perfusion in tumor and muscle. PLoS One 2015;10:e0124665.
   PubMed Web of Science ®Google Scholar
• Mönnich D, Welz S, Thorwarth D, Pfannenberg C, Reischl G, Mauz PS, et al. Robustness of quantitative hypoxia PET image analysis for predicting local tumor control. Acta Oncol 2015;54:1364–1369.
   PubMed Web of Science ®Google Scholar
• Elas M, Ahn KH, Parasca A, Barth ED, Lee D, Haney C, Halpern HJ. Electron paramagnetic resonance oxygen images correlate spatially and quantitatively with Oxylite oxygen measurements. Clin Cancer Res 2006;12:4209–4217.
   PubMed Web of Science ®Google Scholar
• Giatromanolaki A, Koukourakis MI, Sivridis E, Pastorek J, Wykoff CC, Gatter KC, Harris AL. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res 2001;61:7992–7998.
   PubMed Web of Science ®Google Scholar
• Parks SK, Chiche J, Pouyssegur J. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011;226:299–308.
   PubMed Web of Science ®Google Scholar
• Loncaster JA, Harris AL, Davidson SE, Logue JP, Hunter RD, Wycoff CC, et al. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001;61:6394–6399.
   PubMed Web of Science ®Google Scholar
• Potter CP, Harris AL. Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 2003;89:2–7.
   PubMed Web of Science ®Google Scholar
• Lee JW, Bae SH, Jeong JW, Kim SH, Kim KW. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med 2004;36:1–12.
   PubMed Web of Science ®Google Scholar
• Busk M, Jakobsen S, Horsman MR, Mortensen LS, Iversen AB, Overgaard J, et al. PET imaging of tumor hypoxia using 18F-labeled pimonidazole. Acta Oncol 2013;52:1300–1307.
   PubMed Web of Science ®Google Scholar
• Chou SC, Azuma Y, Varia MA, Raleigh JA. Evidence that involucrin, a marker for differentiation, is oxygen regulated in human squamous cell carcinomas. Br J Cancer 2004;90:728–735.
   PubMed Web of Science ®Google Scholar
• Gross MW, Karbach U, Groebe K, Franko AJ, Mueller-Klieser W. Calibration of misonidazole labeling by simultaneous measurement of oxygen tension and labeling density in multicellular spheroids. Int J Cancer 1995;61:567–573.
   PubMed Web of Science ®Google Scholar
• Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood–brain barrier. Neurobiol Dis 2010;37:13–25.
   PubMed Web of Science ®Google Scholar
• Tabanor K, Lee P, Kiptoo P, Choi IY, Sherry EB, Eagle CS, et al. Brain delivery of drug and MRI contrast agent: detection and quantitative determination of brain deposition of CPT-Glu using LC-MS/MS and Gd-DTPA using magnetic resonance imaging. Mol Pharm 2016;13:379–390.
   PubMedGoogle Scholar
• Bernsen HJ, Rijken PF, Peters H, Raleigh JA, Jeuken JW, Wesseling P, van der Kogel AJ. Hypoxia in a human intracerebral glioma model. J Neurosurg 2000;93:449–454.
   PubMed Web of Science ®Google Scholar
• Newman HF, Bleehen NM, Ward R, Workman P. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03–8799 (pimonidazole) and SR 2508 (etanidazole). Int J Radiat Oncol Biol Phys 1988;15:677–684.
   PubMed Web of Science ®Google Scholar
• Lumata L, Kovacs Z, Sherry AD, Malloy C, Hill S, van Tol J, et al. Electron spin resonance studies of trityl OX063 at a concentration optimal for DNP. Phys Chem Chem Phys PCCP 2013;15:9800–9807.
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591–602.
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood–brain barrier drug targeting: the future of brain drug development. Mol Interv 2003;3:90–105, 51.
   PubMedGoogle Scholar
• Deeken JF, Loscher W. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res Off J Am Assoc Cancer Res 2007;13:1663–1674.
   PubMed Web of Science ®Google Scholar
• Schneider SW, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, Senner V, Paulus W. Glioblastoma cells release factors that disrupt blood–brain barrier features. Acta Neuropathol 2004;107:272–276.
   PubMed Web of Science ®Google Scholar
• Rapoport SI. Osmotic opening of the blood–brain barrier: principles, mechanism, and therapeutic applications. Cell Mol Neurobiol 2000;20:217–230.
   PubMed Web of Science ®Google Scholar
• Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, Pluhar GE, et al. Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression. J NeuroOncol 2007;85:133–148.
   PubMed Web of Science ®Google Scholar
• Corroyer-Dulmont A, Pérès EA, Petit E, Durand L, Marteau L, Toutain J, et al. Noninvasive assessment of hypoxia with 3-[18F]-fluoro-1-(2-nitro-1-imidazolyl)-2-propanol ([18F]-FMISO): a PET study in two experimental models of human glioma. Biol Chem 2013;394:529–539.
   PubMed Web of Science ®Google Scholar
• Hovinga KE, Stalpers LJ, van Bree C, Donker M, Verhoeff JJ, Rodermond HM, et al. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines – a clue to radioresistance? J NeuroOncol 2005;74:99–103.
   PubMed Web of Science ®Google Scholar
• Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1alpha, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011;11:167.
   PubMed Web of Science ®Google Scholar
• Harada H, Inoue M, Itasaka S, Hirota K, Morinibu A, Shinomiya K, et al. Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels. Nat Commun 2012;3:783.
   PubMed Web of Science ®Google Scholar
• Wang J, Klem J, Wyrick JB, Ozawa T, Cunningham E, Golinveaux J, et al. Detection of hypoxia in human brain tumor xenografts using a modified comet assay. Neoplasia NY 2003;5:288–296.
   PubMed Web of Science ®Google Scholar
• Shen J, Sood R, Weaver J, Timmins GS, Schnell A, Miyake M, et al. Direct visualization of mouse brain oxygen distribution by electron paramagnetic resonance imaging: application to focal cerebral ischemia. J Cereb Blood Flow Metab 2009;29:1695–1703.
   PubMed Web of Science ®Google Scholar
• Janssen HL, Hoebers FJ, Sprong D, Goethals L, Williams KJ, Stratford IJ, et al. Differentiation-associated staining with anti-pimonidazole antibodies in head and neck tumors. Radiother Oncol 2004;70:91–97.
   PubMed Web of Science ®Google Scholar
• Krishna MC, Matsumoto S, Saito K, Matsuo M, Mitchell JB, Ardenkjaer-Larsen JH. Magnetic resonance imaging of tumor oxygenation and metabolic profile. Acta Oncol 2013;52:1248–1256.
   PubMed Web of Science ®Google Scholar